Mehrishi JN - Search Results

1

Reduction in high blood tumor necrosis factor-alpha levels after manipulative therapy in 2 cervicogenic headache patients.

Ormos G, Mehrishi JN, Bakács T. Ormos G, et al. Among authors: mehrishi jn. J Manipulative Physiol Ther. 2009 Sep;32(7):586-91. doi: 10.1016/j.jmpt.2009.08.006. J Manipulative Physiol Ther. 2009. PMID: 19748410 Review.

2

Ipilimumab (Yervoy) and the TGN1412 catastrophe.

Bakacs T, Mehrishi JN, Moss RW. Bakacs T, et al. Among authors: mehrishi jn. Immunobiology. 2012 Jun;217(6):583-9. doi: 10.1016/j.imbio.2011.07.005. Epub 2011 Jul 7. Immunobiology. 2012. PMID: 21821307 Review.

3

T cells survey the stability of the self: a testable hypothesis on the homeostatic role of TCR-MHC interactions.

Bakács T, Mehrishi JN, Szabados T, Varga L, Szabó M, Tusnády G. Bakács T, et al. Among authors: mehrishi jn. Int Arch Allergy Immunol. 2007;144(2):171-82. doi: 10.1159/000103282. Epub 2007 May 30. Int Arch Allergy Immunol. 2007. PMID: 17541288

4

A novel method of CD34+ cell separation from umbilical cord blood.

Mehrishi JN, Bakács T. Mehrishi JN, et al. Transfusion. 2013 Nov;53(11):2675-80. doi: 10.1111/trf.12123. Epub 2013 Feb 22. Transfusion. 2013. PMID: 23432618

5

Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy).

Bakacs T, Mehrishi JN, Szabó M, Moss RW. Bakacs T, et al. Among authors: mehrishi jn. Pharmacol Res. 2012 Aug;66(2):192-7. doi: 10.1016/j.phrs.2012.03.015. Epub 2012 Apr 6. Pharmacol Res. 2012. PMID: 22503629

6

Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering?

Bakács T, Mehrishi JN. Bakács T, et al. Among authors: mehrishi jn. BMC Cancer. 2010 Jun 2;10:251. doi: 10.1186/1471-2407-10-251. BMC Cancer. 2010. PMID: 20525172 Free PMC article.

7

Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus.

Bakács T, Mehrishi JN. Bakács T, et al. Among authors: mehrishi jn. Vaccine. 2004 Nov 15;23(1):3-13. doi: 10.1016/j.vaccine.2004.08.005. Vaccine. 2004. PMID: 15519701 Review.

8

Current and historical perspectives on methodological flaws in processing umbilical cord blood.

Mehrishi JN. Mehrishi JN. Transfusion. 2013 Nov;53(11):2667-74. doi: 10.1111/trf.12122. Epub 2013 Feb 22. Transfusion. 2013. PMID: 23432602

9

Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.

Bakacs T, Mehrishi JN. Bakacs T, et al. Among authors: mehrishi jn. Immunobiology. 2015 May;220(5):624-5. doi: 10.1016/j.imbio.2014.11.019. Epub 2014 Dec 6. Immunobiology. 2015. PMID: 25638260

10

Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials.

Mehrishi JN, Szabó M, Bakács T. Mehrishi JN, et al. Vaccine. 2007 May 4;25(18):3517-23. doi: 10.1016/j.vaccine.2007.02.078. Epub 2007 Mar 15. Vaccine. 2007. PMID: 17397974

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results